| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802882401016 | 288240101 | FIRMAGON PS.INJ.SOL 80MG/VIAL BTx 1VIAL x6ML SOLV+1SYR+1 ΒΕΛΟΝΑ ΑΝΑΣΥΣΤΑΣΗΣ+1ΒΕΛΟΝΑ ΕΝΕΣΗΣ SOLV+1SYR+1 ΒΕΛΟΝΑ ΑΝΑΣΥΣΤΑΣΗΣ+1ΒΕΛΟΝΑ ΕΝΕΣΗΣ | 111.35 | 116.81 | 143.63 |
| 05/2018 | 2802882402013 | 288240201 | FIRMAGON PS.INJ.SOL 120MG/VIAL BTx2VIALS+2VIALSx6ML SOLV +2SYR+2 ΒΕΛΟΝEΣ ΑΝΑΣΥΣΤΑΣΗΣ+2ΒΕΛΟΝΕΣ ΕΝΕΣΗΣ | 203.25 | 206.30 | 244.92 |
Degaralix is used for the management of advanced prostate cancer. Its action ultimately results in a reduction in circulating androgens, which provides a therapeutic benefit by reducing the growth stimulus used by hormone-sensitive malignant prostate tissue.
Degarelix forms a depot at the site of injection after subcutaneous administration from which the drug slowly released into circulation. Peak plasma concentrations of degarelix generally occur within 2 days following subcutaneous administration of a single 240-mg dose at a concentration of 40 mg/mL.
23-61 days